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Background: Stents are recommended in patients with dysphagia caused by esophageal stricture, but an ideal
stent does not currently exist. Thus, studies on new esophageal stents are necessary, and suitable animal models
are desperately needed for these studies. The aim of this study was to establish a model of malignant esophageal
stricture in rabbit for studies on stent innovation.
Methods: A total of 38 New Zealand white rabbits were used in this study. Using the endoscopic submucosal
injection technique, VX2 fragments were inoculated into the submucosal layer of the rabbit thoracic esophagus,
and an endoscopic follow-up was subsequently performed to observe the tumor development and progression.
The self-expandable metal stents were randomly deployed in rabbits with severe esophageal stricture to investigate
the safety and feasibility of the animal models for stenting.
Results: An endoscopic implantation procedure for VX2 tumors was completed in 34/38 rabbits, and tumor
development was confirmed in 30/34 animals. The success rate of the endoscopic implantation and tumor
development were 89.4% (95% CI, 79.6% to 99.2%) and 88.2% (95% CI, 76.9% to 99.5%) respectively. During the
endoscopic follow-up period, severe esophageal stricture occurred in 22/30 rabbits with a rate of 73.3% (95% CI, 57.5%
to 89.1%), and 12/22 models received stent placement. During and after stent implantation, no severe stent-related
complication or mortality occurred in the animal models. The rabbits that received stent placement survived longer
than those without stent implantation (the mean survival time: 53.9 days versus 40.3 days, P = 0.016).
Conclusion: The endoscopic method is a safe and effective method for establishing a malignant esophagostenosis
model in rabbits. This model can simulate the human body environment for stent deployment and is an excellent tool
for the study of stent innovation for the treatment of esophageal cancer.
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Esophageal cancer (EC) is the sixth leading cause of cancer-
related mortality and the eighth most common cancer
worldwide [1,2]. Treatment of esophageal carcinoma re-
mains challenging but is best approached using a multidis-
ciplinary team. Stents are recommended in patients with
dysphagia caused by esophageal stricture, and an optimal
stent should have features, such as being easy to deploy,
staying in place, reducing tumor ingrowth or overgrowth,
and causing minimal to no discomfort [3-5]. However, the
ideal stent does not currently exist, and studies on new
esophageal stents are necessary and significant. Thus, suit-
able animal models are desperately needed for these studies.
Theoretically, a good animal model of EC for stenting
should be able to mimic the esophagostenosis features
of the human disease and be sufficiently large to perform
minimally invasive procedures designed for humans.
However, there is currently a severe lack of an excellent
animal model of EC to study stents [6-9].
The VX2 tumor model, which was originally proposed
by Shope and Hurst [10] in 1933, has been developed in
the organs of rabbits, including the liver, kidney, lung,
head and neck [11-14]. Although the rabbit model belongs
to moderate-to-large-sized models and has been used to
study EC in relevant research, there have been no reports
on establishment of a rabbit model on malignant esopha-
gostenosis, which is available for stent implantation.
Here, we introduce an endoscopic method for the de-
velopment of a rabbit model of malignant esophagoste-
nosis, and further investigate the safety and feasibility of
stent implantation in this model. This is the first studyFigure 1 Stent and its delivery system. (A) The delivery system for the s
25 mm in length, and its partial length is covered with a silicone membranwhere rabbits with esophageal malignant tumors were
used for stent development procedures.
Material and methods
Animals and tumors
Male or female New Zealand White rabbits weighing be-
tween 2.5 and 3.0 kg were obtained from The Jiangsu Agri-
cultural Academy of Science in China and food and water
were provided ad libitum. All experimental procedures
were approved by the Animal Care and Use Subcommittee
at Nanjing Medical University.
Donor rabbits and implantation preparation
Rabbits with hind limb tumors (donor) were used to propa-
gate and maintain VX2 tumors. Approximately 2 to 3 pieces
of thawed VX2 tumor tissue fragments (approximately
0.5 mm3) that, were previously stored in liquid nitrogen
were injected deep into the hind limb of gluteal muscles of
rabbits anesthetized using an intramuscular injection of
35-mg/kg pentobarbital sodium (Sigma Chemical Co.,
St. Louis, MO, USA). Three weeks after implantation,
the animals were sacrificed and the hind limb tumors
were harvested and immediately processed. All VX2 tu-
mors were cleaned from the surrounding tissue and
gross necrotic portions of the tumors were removed.
The collected tumors were cut into small pieces (ap-
proximately 0.5 mm3) and preserved in saline for frag-
ment implantation. approximately 0.3 ml saline solution
with 4 pieces of tumor fragments were placed in a 2-ml
syringe on ice until they were injected into the recipient
rabbit’s esophagus.tent. (B) The self-expandable metal stent is 8 mm in diameter and
e.
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The rabbits were first anesthetized after 24 h of fasting
with free access to water and then placed in the left lateral
decubitus position. An endoscope (Olympus GIFXP260,
Japan) was inserted into the thoracic esophagus. Using a
fine endoscopic needle (the inner core of an endoscopic
needle, Olympus, MAJ-68, 23-gauge), 0.5 ml saline was
injected into the submucosal layer to elevate the mucosa
layer. Next, a puncture was made using a modified endo-
scopic needle (Olympus, MAJ-68, with an oblique cut in
the front, approximately 20-gauge) across the mucosa into
the submucosal layer and the success of the puncture was
confirmed by further elevation of the mucosa when saline
was injected. About 0.3 ml saline containing 4 tumor
pieces was then injected into the submucosal layer of rab-
bits esophagus (an additional movie file shows this in
more detail, see Additional file 1). A second 0.3 ml saline
was injected to rinse the needles and to collect the
remaining pieces. After implantation, the rabbits were
given an auricular vein infusion and fasted for 24 h.
Endoscopic follow-up
Endoscopic examinations were performed once a week after
implantation to observe tumor growth and the degree ofFigure 2 Procedure for stent placement. (A) Fluoroscopy showed a mal
endoscope (yellow arrow) was used for injection of the contrast. (B) Fluoro
also confirmed using an endoscope (yellow arrow). (C) Endoscopic view of
was on the right of the tumor (black arrow). (D) After stent placement, the
tumor was outside of stent, but within the extension of the stent (yellow aesophageal stenosis. Tumor development was determined
using endoscopy and biopsy. Three grades were used to
evaluate the esophageal stenosis under endoscopy: mild
stenosis for tumors less than or equal to 1/3 of the lumen
diameter, moderate stenosis for tumors more than 1/3 but
less than or equal to 2/3 of the lumen diameter, and severe
stenosis for tumors more than 2/3 of the lumen diameter.
Stent implantation
The stents was randomly implanted in some models
when the degree of esophageal stricture became severe,
the remainder without stents acted as controls for the
survival study. The self-expandable metal stent (8 mm in
diameter and 25 mm in length) was designed and manu-
factured (Garson Company, Changzhou City, China),
and its partial length was covered with a silicone mem-
brane (Figure 1). Using X-ray fluoroscopy, a guidewire
was first inserted across the stricture into the stomach.
Next, the delivery device was gently passed over the
guidewire, and the restraining tube was retracted to re-
lease the stent within the stricture (Figure 2). As soon as
the stent was deployed, correct positioning of the stent
was assessed endoscopically. Next, endoscopic and
fluoroscopic examinations were performed every weekignant stricture (black arrow) in the thoracic esophagus of a rabbit. The
scopic view of the stent implanted at the desired location, which was
the tumor intra-luminal growth (yellow arrow); the esophageal lumen
endoscopic view of the stent at an ideal location revealed that the
rrow).
Figure 3 Tumor development. (A) Endoscopic view of tumor growth one week after implantation (black arrow). (B) Microscopy confirmed the
tumor growth.
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models, inclouding fistulization/perforation, bleeding, stent
migration, esophageal restenosis, airway compromise and
procedure-related mortality.
Survival time
The survival time of all rabbits demonstrated severe
esophageal stricture was recorded, independent of the
status of stent placement. The rabbits were fed separ-
ately in cages to daily observe the quantity of food and
water. Paste food or liquid food (vegetable juices) were
provided for animals with dysphagia or a 50% reduction
of food intake. A humane endpoint was used in this
study, in which the animal models were humanely eu-
thanized when they could not have any food or water for
several days and their health was extremely weak, such
that they could not stand. For the euthanasia procedure,
the animal was first anesthetized via an intramuscular
injection of 35-mg/kg pentobarbital sodium using the
ear venous, and then with a injection of 30 ml air.
Data analysis
We calculated the success rate of tumor production,
inclouding that of endoscopic implantation and tumor de-
velopment. The rate of severe esophageal stricture and the
rate of immediate and late complication of stents placemenFigure 4 Degree of esophagostenosis. The endoscopic follow-up showe
(C) a severe stricture in a rabbit. In the image, the black arrows indicate thewere also investigated. The Kaplan-Meier method with the
log rank test was used to analyze the survival of rabbits
with or without stents. The statistical significance was set
at the P < 0.05 level. All statistical tests were performed
with the SPSS 16.0 software.Results
Success rate of tumor production
A total of 38 rabbits were used in this study. Thirty-four
rabbits were successfully implanted with VX2 fragments
in the esophagus and the success rate of endoscopic im-
plantation was 89.4% (95% CI, 79.6% to 99.2%). Four
rabbits were removed from the study because of the
esophageal perforations during the endoscopic implant-
ation and two injured rabbits (5.3%) died after conserva-
tive treatments. After implantation, tumor development
was confirmed (Figure 3) in 30/34 rabbits and the suc-
cess rate was 88.2% (95% CI, 76.9% to 99.5%).Degree of esophageal stenosis
During the endoscopic follow-up after tumor implant-
ation, severe stricture was observed in 22/30 rabbits
(Figure 4), and the rate was 73.3% (95% CI, 57.5% to
89.1%). Mild-to-moderate stricture was observed in 8/30
rabbits and the rate was 26.7% (95% CI, 10.9% to 42.5%).d (A) a mild stricture in a rabbit; (B) a moderate stricture in a rabbit;
tumors and the yellow arrows indicate the esophageal lumen.
Figure 5 Complications of stent placement. (A) During stent implantation, fluoroscopic view of stent migration to the stomach in a rabbit.
(B) Endoscopic view of the esophageal re-stenosis at the distal stent in an animal model three weeks after stent placement.
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Among 22 models with severe esophageal stricture, 12
rabbits were smoothly implanted with esophageal stents,
and the remaining 10 rabbits served as controls for the
survival study. During and after stent deployment, stent
migration, esophageal restenosis (Figure 5) and airway
compromise occurred in 2/12 (16.7%), 1/12 (8.3%) and
1/12 (8.3%) rabbits respectively. There was no severe
stent-related complication or mortality.
Survival time of the models
The longest survival time of rabbits with stent implantation
was 74 days and the shortest survival time was 28 daysFigure 6 Survival curve of the rabbits with severe esophagostenosis.
benefit (P < 0.05) for models with stent placement (blue curve), compared
esophagostenosis (green curve).with a mean survival time of 53.9 ± 13.4 days. However, the
longest survival time of rabbits without stents deployed
was 59 days, and the shortest survival time was 24 days
with a mean survival time of 40.3 ± 11.3 days, which was
significantly different (P = 0.016) in the survival time be-
tween the two groups (Figure 6).
Discussion
Despite having a higher success rate of tumor growth
[15,16] compared to VX2 cells, the VX2 fragments were
difficult to implant into the rabbit esophagus, independ-
ent of the endoscopic or surgical procedure selected.
Compared with the surgical method, the endoscopicGraph of Kaplan–Meier survival analysis showing a significant survival
to those without stent deployment, but similarly demonstrated severe
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incidence of esophageal perforation when using large
needles to implant the VX2 fragments. Thus, we intro-
duced the submucosal injection technique [17,18] for
our endoscopic procedure to decrease the complications
by enlarging the space of the submucosal layer of the
esophagus. In the current study, the endoscopic method
demonstrated a high success rate of implantation indi-
cating that it is a safe and effective method for the estab-
lishment of a malignant esophagostenosis model.
Esophageal stenosis is a predominant pathological fea-
ture of EC in the clinic because it promotes rapid deteri-
oration and death [19,20]. In the present study, our
model showed a high rate of severe esophagostenosis,
which is a very important indication for stenting. We
proposed that this characteristic formation might be as-
sociated with the tumor submucosal layer implantation,
which contributs to the tumor intra-luminal growth.
In many preclinical studies, large-sized animal models,
such as the dog and pig, have been generally used for
stenting, but these animals were not under disease condi-
tions, despite the fact that they could simulate the human
body environment for esophageal stent deployment. Thus,
they were only used to assess the safety of stenting
[21-23]. Furthermore, small animal models, such as mice,
were immunodeficient and may potentially exhibit malig-
nant esophagostenosis, this, could be used to study the ef-
ficiency and mechanism of stenting; however, these small
animal models can not allow for stenting, according to the
procedures designed for humans [24-26]. Thus, they are
unsuitable and are seldom used for studies on stents. The
rabbit model of malignant esophagostenosis developed in
this study not only exhibits the feature of malignant eso-
phagostenosis, commendably mimicking that of human
EC and showing potential use for research on the effi-
ciency and mechanism of stents, but it could also simulate
the human body environment for stenting according to
the procedures used for humans.
The overall complication rate and primary success rate
of self-expanding esophageal stenting in clinical research
were approximately 30% and 97.2%, respectively [27,28].
In this study, all of the procedures of the stent implant-
ation were smoothly completed, and there was no rabbit
that had severe stent-related complications [29,30], such
as fistulization/perforation or bleeding, and there was no
procedure-related mortality, although the events of stent
migration, esophageal re-stenosis and airway comprom-
ise occurred with a total complication rate of 33.3% dur-
ing and after stent implantation. These results indicated
that it is safe and feasible to implant an esophageal stent
into our animal models. Moreover, the survival time of
rabbits with stent placement was longer compared to
rabbits without stent deployment indicating that our
models could endure stent implantation and benefitfrom the stents. This finding suggested that our animal
model represents an ideal tool for the study of esopha-
geal stents for EC.
The limitation of our animal model is that it is an
orthotopic allograft tumor model and cannot be main-
tained the routine course of esophageal cancers. This
study focused on whether the animal model is suitable
for stent implantation and may neglect other features
and utility of this animal model.
In conclusion, the endoscopic method is safe and effective
for the development of a rabbit model of malignant esopha-
gostenosis to mimic the progression of this human disease.
This model can simulate human the body environment for
stent deployment and is an excellent tool for studying stent
innovation for the treatment of esophageal cancer.
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